Milestone Asset Management LLC Grows Stock Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Milestone Asset Management LLC grew its position in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 5.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 163,789 shares of the company’s stock after buying an additional 8,662 shares during the quarter. Milestone Asset Management LLC owned 0.18% of Caribou Biosciences worth $260,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Erste Asset Management GmbH acquired a new position in Caribou Biosciences in the 3rd quarter valued at about $28,000. AQR Capital Management LLC acquired a new position in shares of Caribou Biosciences in the second quarter valued at approximately $30,000. China Universal Asset Management Co. Ltd. increased its stake in Caribou Biosciences by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock worth $34,000 after buying an additional 6,768 shares during the period. Intech Investment Management LLC acquired a new stake in Caribou Biosciences during the 3rd quarter worth approximately $43,000. Finally, Point72 DIFC Ltd boosted its position in Caribou Biosciences by 389.4% in the 2nd quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock valued at $49,000 after buying an additional 23,995 shares during the period. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Price Performance

Shares of NASDAQ CRBU opened at $1.31 on Friday. The business has a 50-day moving average of $1.78 and a two-hundred day moving average of $1.98. The company has a market capitalization of $118.62 million, a price-to-earnings ratio of -0.79 and a beta of 2.34. Caribou Biosciences, Inc. has a 1 year low of $1.30 and a 1 year high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last posted its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. The firm had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. As a group, equities research analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CRBU. Bank of America reduced their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Finally, Citigroup cut their target price on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.